✦ LIBER ✦

P44 NNBC-3 Europe: A prospective clinical trial on riskestimation and optimization of adjuvant chemotherapy in node-negative breast cancer patients

✍ Scribed by F. Herbst; N. Harbeck; K. Gauger; N. Gaskill; F. Sweep; C. Meisner; M. Schmitt; F. Jaenicke; C. Thomssen

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A trial to improve risk estimation and r

✍ V. Mueller; C. Thomssen; N. Harbeck; R. Paridens; F. Herbst; H. Selbmann; C. Mei 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 392 KB

P44 Is tumor-biological risk-assessment

✍ M. Persing; N. Harbeck; M. Vetter; A. Guerts; M. Zerm; D. Paepke; M. Schmidt; C. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 62 KB

P180 Molecular types, uPA/PAI-1, clinica

✍ E.J. Kantelhardt; M. Vetter; K. Spinda; A. Lingner; M. Schmidt; P.M. Martin; R. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 40 KB

NNBC-3 Europe study: a trial to improve

✍ F Herbst; N Harbeck; V.P.R Mueller; A Oben; C Meisner; F Sweep; M Schmitt; F Jae 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 171 KB

The influence of classical prognostic fa

✍ S Susnjar; I Kezic; Z Neskovic-Konstantinovic; D Gavrilovic; D Nikolic-Vukosavlj 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 319 KB

Adjuvant chemotherapy and timing of tamo

✍ Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burto 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 145 KB